# Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

> **NCT06690541** · — · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 100 (estimated)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **DRUG:** Lorlatinib 100 mg

## Key facts

- **NCT ID:** NCT06690541
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-10
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690541, "Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06690541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*